SCHNELL DAVID 4
4 · Trubion Pharmaceuticals, Inc · Filed Oct 28, 2010
Insider Transaction Report
Form 4
SCHNELL DAVID
DirectorOther
Transactions
- Disposition to Issuer
Stock option (right to purchase)
2010-10-28−5,000→ 0 totalExercise: $6.63Exp: 2018-05-26→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock option (right to purchase)
2010-10-28−5,000→ 0 totalExercise: $3.45Exp: 2020-05-26→ Common Stock (5,000 underlying) - Disposition to Issuer
Common Stock
2010-10-28−1,829,765→ 1,829,765 total(indirect: By Prospect Venture Partners II, L.P.) - Disposition to Issuer
Common Stock
2010-10-28−27,866→ 27,866 total(indirect: By Prospect Associates II, L.P.) - Disposition to Issuer
Stock option (right to purchase)
2010-10-28−12,500→ 0 totalExercise: $13.78Exp: 2016-10-24→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock option (right to purchase)
2010-10-28−5,000→ 0 totalExercise: $19.08Exp: 2017-05-25→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock option (right to purchase)
2010-10-28−5,000→ 0 totalExercise: $2.28Exp: 2019-05-27→ Common Stock (5,000 underlying)
Footnotes (9)
- [F1]Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $2,497,629.23 cash, (b) 300,264 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 1,829,765 contingent value rights, which represent the right to receive possible additional cash payments.
- [F2]Prospect Management Co. II, LLC, of which the reporting person is one of the managing directors, is the sole general partner of Prospect Venture Partners II, L.P. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- [F3]Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $38,037.09 cash, (b) 4,572 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 27,866 contingent value rights, which represent the right to receive possible additional cash payments.
- [F4]Prospect Management Co. II, LLC, of which the reporting person is one of the managing directors, is the sole general partner of Prospect Associates II, L.P. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- [F5]This option, which was 100% vested on October 23, 2009, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
- [F6]This option, which was 100% vested on May 27, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
- [F7]This option, which was 100% vested on May 15, 2009, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
- [F8]This option, which was 100% vested on May 26, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $11,350, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 5,000 contingent value rights, which represents the right to receive possible additional future cash payments.
- [F9]This option, which was to be 100% vested on May 25, 2011, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $5,500, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 5,000 contingent value rights, which represents the right to receive possible additional future cash payments.